Publication:
Cancer stem cell as therapeutic target for melanoma treatment

Thumbnail Image
Files
Alamodi-31-1291-1301-2016.pdf(4.5 MB)
Date
2016
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Alamodi, Abdulhadi A. ; Eshaq, Abdulaziz M. ; Hassan, Sofie Yasmin ; Hmada, Youssef Al ; El Jamal, Siraj M. ; Fothan, Ahmed M. ; Arain, Omair M. ; Hassan, Sarah-Lilly ; Haikel, Youssef ; Megahed, Mosaad ; Hassan, Mohamed
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de BiologĂ­a Celular e HistologĂ­a
publication.page.editor
publication.page.department
DOI
DOI: 10.14670/HH-11-791
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Human malignant melanoma is a highly aggressive skin tumor that is characterized by its extraordinary heterogeneity, propensity for dissemination to distant organs and resistance to cytotoxic agents. Although chemo- and immune-based therapies have been evaluated in clinical trials, most of these therapeutics do not show significant benefit for patients with advanced disease. Treatment failure in melanoma patients is attributed mainly to the development of tumor heterogeneity resulting from the formation of genetically divergent subpopulations. These subpopulations are composed of cancer stem-like cells (CSCs) as a small fraction and non-cancer stem cells that form the majority of the tumor mass. In recent years, CSCs gained more attention and suggested as valuable experimental model system for tumor study. In melanoma, intratumoral heterogeneity, progression and drug resistance result from the unique characteristics of melanoma stem cells (MSCs). These MSCs are characterized by their distinct protein signature and tumor growth-driving pathways, whose activation is mediated by driver mutation-dependent signal. The molecular features of MSCs are either in a causal or consequential relationship to melanoma progression, drug resistance and relapse. Here, we review the current scientific evidence that supports CSC hypothesis and the validity of MSCs-dependent pathways and their key molecules as potential therapeutic target for melanoma treatment.
publication.page.subject
Melanoma , Cancer stem-like cells , Melanoma stem cells , Signaling pathways , Therapy
Citation
Histology and Histopathology, Vol.31, nÂş12, (2016)
URI
http://hdl.handle.net/10201/114745
item.page.embargo
Collections
Histology and histopathology Vol.31,nÂş 12 (2016)
Ir a EstadĂ­sticas